Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


VETC (vessels encapsulating tumor clusters) is a powerful predictor of aggressive hepatocellular carcinoma.

Renne SL, Woo HY, Allegra S, Rudini N, Yano H, Donadon M, Viganò L, Akiba J, Lee HS, Rhee H, Park YN, Roncalli M, Di Tommaso L.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30814. [Epub ahead of print]


Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.

Fang JH, Xu L, Shang LR, Pan CZ, Ding J, Tang YQ, Liu H, Liu CX, Zheng JL, Zhang YJ, Zhou ZG, Xu J, Zheng L, Chen MS, Zhuang SM.

Hepatology. 2018 Dec 1. doi: 10.1002/hep.30366. [Epub ahead of print]


Epithelial-Mesenchymal Transition is Superior to Vessels-Encapsulate Tumor Cluster in Promoting Metastasis of Hepatocellular Carcinoma: a Morphological Evidence.

He C, Zhou Z, Jiang H, Yin Z, Meng S, Zhang J, Huang P, Xu K, Bian L, Xiao Z, Wang J.

J Cancer. 2017 Jan 1;8(1):39-47. doi: 10.7150/jca.16736. eCollection 2017.


A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner.

Fang JH, Zhou HC, Zhang C, Shang LR, Zhang L, Xu J, Zheng L, Yuan Y, Guo RP, Jia WH, Yun JP, Chen MS, Zhang Y, Zhuang SM.

Hepatology. 2015 Aug;62(2):452-65. doi: 10.1002/hep.27760. Epub 2015 Apr 22.


MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.

Zhou HC, Fang JH, Shang LR, Zhang ZJ, Sang Y, Xu L, Yuan Y, Chen MS, Zheng L, Zhang Y, Zhuang SM.

J Pathol. 2016 Dec;240(4):450-460. doi: 10.1002/path.4804. Epub 2016 Oct 18.


[The relationship between vimentin protein expression in endothelial cells and contrast-enhanced ultrasound characters in VETC (+ ) hepatocellular carcinoma].

Lan CY, Ling B, Guo WW, Yin W, Zhong XG, Han YM, Dong XF.

Zhonghua Zhong Liu Za Zhi. 2018 Feb 23;40(2):105-109. doi: 10.3760/cma.j.issn.0253-3766.2018.02.005. Chinese.


Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.


Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J.

J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.


Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma.

Okabe H, Yoshizumi T, Yamashita YI, Imai K, Hayashi H, Nakagawa S, Itoh S, Harimoto N, Ikegami T, Uchiyama H, Beppu T, Aishima S, Shirabe K, Baba H, Maehara Y.

PLoS One. 2018 Sep 14;13(9):e0203856. doi: 10.1371/journal.pone.0203856. eCollection 2018.


Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.

Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY.

World J Gastroenterol. 2013 Mar 21;19(11):1811-9. doi: 10.3748/wjg.v19.i11.1811.


Macrotrabecular Hepatocellular Carcinoma: An Aggressive Subtype of Hepatocellular Carcinoma.

Jeon Y, Benedict M, Taddei T, Jain D, Zhang X.

Am J Surg Pathol. 2019 Jul;43(7):943-948. doi: 10.1097/PAS.0000000000001289.


[CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy].

Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY, Hu WY, Han B.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):753-8. doi: 10.3760/cma.j.issn.0253-3766.2012.10.008. Chinese.


Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma.

Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, Seo DD, Jang MK, Yu E, Kim KW.

Hepatology. 2008 Mar;47(3):929-36. doi: 10.1002/hep.22124.


Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.

Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ.

Hepatobiliary Pancreat Dis Int. 2010 Jun;9(3):296-305.


Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features.

Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ.

Liver Cancer. 2019 Feb;8(1):24-40. doi: 10.1159/000488540. Epub 2018 May 15.


Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.

Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.

World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.


Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.

Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C.

J Hepatol. 2017 Mar;66(3):552-559. doi: 10.1016/j.jhep.2016.10.038. Epub 2016 Nov 27.


Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.

Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A.

Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5.


Supplemental Content

Support Center